Media stories about Aegerion Pharmaceuticals (NASDAQ:AEGR) have trended somewhat negative recently, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aegerion Pharmaceuticals earned a media sentiment score of -0.08 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.2120917300283 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Aegerion Pharmaceuticals (AEGR) remained flat at $$1.97 on Tuesday. The company has a debt-to-equity ratio of -19.22, a quick ratio of 0.67 and a current ratio of 1.02. Aegerion Pharmaceuticals has a 12 month low of $1.23 and a 12 month high of $10.85.

TRADEMARK VIOLATION WARNING: “Aegerion Pharmaceuticals (AEGR) Getting Somewhat Critical Media Coverage, Study Finds” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at

Aegerion Pharmaceuticals Company Profile

Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.

Insider Buying and Selling by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Receive News & Ratings for Aegerion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.